Latest Research And Development News

Actinogen Medical has reached a key milestone in its XanaMIA phase 2b/3 Alzheimer’s trial with over 100 participants enrolled, setting the stage for an interim analysis in January 2026. The company also secured a $13.8 million non-dilutive R&D funding facility to support ongoing development.

DroneShield Limited has reported record revenue growth in 2Q25, driven by soaring demand for AI-powered counterdrone solutions amid a global surge in defense spending. The company’s expanding $2.33 billion sales pipeline and strong cash position position it well for future growth.

Locate Technologies reported a 5% revenue increase for FY25, driven by strong growth in its Locate2u platform, while Zoom2u faced revenue headwinds. The company also expanded its Bitcoin holdings and raised $2.5 million in capital.

BrainChip Holdings reported a solid June quarter with $13.5 million in cash, increased customer inflows, and a strategic decision to remain listed on the ASX. The company advanced multiple commercial collaborations and expanded its intellectual property portfolio, signaling confidence in its edge AI technology roadmap.

BCAL Diagnostics has reported strong early commercial uptake of its BREASTEST plus non-invasive breast cancer diagnostic test, alongside a new partnership with Cancer Care Associates to expand market reach.

Nexus Minerals has reported a significant new gold discovery at its Wallbrook Gold Project, highlighted by strong drilling results at the Payns Prospect, while progressing permitting for the Crusader-Templar deposit and maintaining a solid cash position.

Noxopharm has initiated its HERACLES clinical trial for SOF-SKN, marking a key milestone for its Sofra platform, while deepening partnerships and actively seeking new funding to sustain development.

Ardea Resources reports significant progress on its Kalgoorlie Nickel Project, completing key drilling and metallurgical work while securing $4.6 million in strategic funding from Sumitomo Metal Mining. The company remains well-funded as its joint venture partners advance the Definitive Feasibility Study.

WA Kaolin Limited reports robust production growth and expanding sales, driven by new technical kaolin grades and strong forward orders for FY26.

Immutep Limited advances its pivotal Phase III lung cancer trial and reports promising results across multiple oncology and autoimmune programs, supported by a solid cash position to fund operations through 2026.

Parkway Corporate Limited reported a strong quarter with $4.22 million in revenue and $0.47 million EBITDA, driven by a major wastewater contract and progress in its innovative Queensland Brine Solutions technology.

Spectur Limited reports a positive operating cash flow for Q4 FY25, driven by revenue growth and cost-cutting, alongside strategic investments in cloud and connectivity technology.